180 related articles for article (PubMed ID: 7757855)
1. FDA set to expand pediatric information in drug product labeling.
Am J Health Syst Pharm; 1995 Feb; 52(4):358. PubMed ID: 7757855
[No Abstract] [Full Text] [Related]
2. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Clin Pharm; 1993 Jan; 12(1):6. PubMed ID: 8428434
[No Abstract] [Full Text] [Related]
3. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
4. Is pediatric labeling really necessary?
Christensen ML; Helms RA; Chesney RW
Pediatrics; 1999 Sep; 104(3 Pt 2):593-7. PubMed ID: 10469796
[No Abstract] [Full Text] [Related]
5. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271
[No Abstract] [Full Text] [Related]
6. FDA off-track on off-label drug promotion.
Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
[No Abstract] [Full Text] [Related]
7. Judge strikes down FDA policies on industry dissemination of off-label information.
Miller JL
Am J Health Syst Pharm; 1999 Sep; 56(17):1695-6. PubMed ID: 10512492
[No Abstract] [Full Text] [Related]
8. Therapeutic orphans.
Shirkey H
Pediatrics; 1999 Sep; 104(3 Pt 2):583-4. PubMed ID: 10469793
[No Abstract] [Full Text] [Related]
9. An update on the therapeutic orphan.
Wilson JT
Pediatrics; 1999 Sep; 104(3 Pt 2):585-90. PubMed ID: 10469794
[No Abstract] [Full Text] [Related]
10. FDA mulls over paperless labeling.
Young D
Am J Health Syst Pharm; 2007 Jun; 64(11):1120, 1122. PubMed ID: 17519446
[No Abstract] [Full Text] [Related]
11. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
Green W
Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
[No Abstract] [Full Text] [Related]
12. FDA notifications. New labeling for Videx pediatric powder.
AIDS Alert; 2009 Aug; 24(8):94-6. PubMed ID: 19705588
[No Abstract] [Full Text] [Related]
13. FDA scrutinizes 'off-label' promotions.
Randall T
JAMA; 1991 Jul; 266(1):11. PubMed ID: 2046119
[No Abstract] [Full Text] [Related]
14. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
[TBL] [Abstract][Full Text] [Related]
15. FDA targets unapproved drugs.
Young D
Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
[No Abstract] [Full Text] [Related]
16. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
Karst KR
Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
[No Abstract] [Full Text] [Related]
17. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
Ren Z; Zajicek A
Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
[No Abstract] [Full Text] [Related]
19. Essential drugs for infants and children: North American perspective.
Kauffman RE
Pediatrics; 1999 Sep; 104(3 Pt 2):603-5. PubMed ID: 10469798
[No Abstract] [Full Text] [Related]
20. Warning label limbo. FDA rule letting generic-drug makers update risk alerts draws heavy flak.
Carlson J
Mod Healthc; 2014 Jun; 44(26):20-2. PubMed ID: 25134408
[No Abstract] [Full Text] [Related]
[Next] [New Search]
